Dr. Hussain on the Treatment of Nonmetastatic CRPC

Maha Hussain, MD, FACP
Published: Wednesday, Jul 25, 2018



Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

One of the most pressing unmet needs in prostate cancer is the treatment of patients with nonmetastatic CRPC, according to Hussain. The phase III PROSPER trial, results of which were presented at the 2018 Genitourinary Cancers Symposium, showed potential for the combination of enzalutamide (Xtandi) and androgen deprivation therapy (ADT) in extending the median metastasis-free survival (MFS) for these patients.

The combination reduced the risk of death by 71% when compared to ADT alone, and the MFS was 36.6 months with enzalutamide plus ADT versus 14.7 months with ADT alone (HR, 0.29; 95% CI, 0.24-0.35; P <.0001). This trial met its primary endpoint of MFS, with close to a 2-year difference between enzalutamide and ADT and ADT alone, Hussain concludes.
SELECTED
LANGUAGE


Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

One of the most pressing unmet needs in prostate cancer is the treatment of patients with nonmetastatic CRPC, according to Hussain. The phase III PROSPER trial, results of which were presented at the 2018 Genitourinary Cancers Symposium, showed potential for the combination of enzalutamide (Xtandi) and androgen deprivation therapy (ADT) in extending the median metastasis-free survival (MFS) for these patients.

The combination reduced the risk of death by 71% when compared to ADT alone, and the MFS was 36.6 months with enzalutamide plus ADT versus 14.7 months with ADT alone (HR, 0.29; 95% CI, 0.24-0.35; P <.0001). This trial met its primary endpoint of MFS, with close to a 2-year difference between enzalutamide and ADT and ADT alone, Hussain concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x